ClotCare: Blood Clots, Stroke, Heart Attack
Saturday, July 13, 2024
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Aspirin and clopidogrel combination less effective and no safer than warfarin therapy in atrial fibrillation

William E. Dager, Pharm.D., FCSHP
December, 2006

Reference: ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun 10;367(9526):1903-12.

The ACTIVE trial involved analysis of several adjuncts for preventing complications in atrial fibrillation. In the ACTIVE W portion, patients assigned to receive open treatment oral anticoagulation targeting an INR of 2-3 (n=3371) were compared to clopidogrel 75mg orally daily plus low dose (75-100mg) aspirin (n=3335). Both groups had similar CHADS2 stroke risk scores. Warfarin was well controlled with 64% of INR values between 2-3. Interm analysis for the incidence of primary outcomes for occurrence of stroke, non-CNS systemic embolus, myocardial infarction or vascular related death suggested a significant benefit with the use of warfarin compared to the combined anti-platelet therapies (relative risk reduction of 8.3%/yr vs 6.5%/year favoring oral anticoagulation p = 0.0008). Because of the clear benefit observed with warfarin, the trial was stopped prematurely. The benefit was especially notable in those patients who had already been receiving oral anticoagulation therapy prior to enrolling into the trial (77% had been on oral anticoagulation prior to randomization). The primary area of benefit with oral anticoagulation therapy was a reduction ischemic stroke with a relative risk reduction of 2.4%/yr vs 1.4%/yr p = 0.0001, or an absolute risk reduction of 1%/yr. Significance was achieved despite the relatively low incidence rate. Most of the benefit was seen with a lower incidence of small, non-disabling strokes and non-CNS systemic embolism. The incidence of major hemorrhage was similar between the groups (relative risk 2.4% for clopidogrel/ASA vs 2.2% for warfarin).

For patients who were not receiving oral anticoagulation therapy prior to enrolling in the trial, a benefit of improved outcomes was noted at approximately one year while incurring a higher rate of major bleeding. Those subsequently randomized to receive oral anticoagulation were twice as likely to stop therapy during the trial. In contrast, patients previously receiving an oral anticoagulant at trial entry did not show any benefit in reduced major bleeding until approximately one year out, but a notable benefit in primary outcome was observed from the onset. Overall, the observations of the ACTIVE W trial suggest a benefit with continued well-controlled oral anticoagulation therapy if the individual was already receiving it. It still leaves in question the management of individuals who are not receiving oral anticoagulants or antiplatelet therapy, or have previously stopped such therapy.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-860-0487
Send comments to
Saturday, July 13, 2024